Investigational drug · Phase 3
JNJ-78934804
Also called: JNJ-4804
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colitis, Ulcerative, Crohn's Disease, Crohn Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "JNJ-78934804"
First trial start
2022
Jul 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-78934804", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colitis, Ulcerative
- Crohn's Disease
- Crohn Disease
Approved drugs for the same conditions: Crohn's disease · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-78934804" as an intervention, largest first.
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05242471 · 703 participants · Start Jul 22, 2022 · Primary completion May 23, 2025
Drug: Guselkumab; Golimumab and 2 more · For: Crohn's Disease
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 456 sites in all
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07577856 · 644 participants (planned) · Start May 23, 2026 · Primary completion Aug 11, 2028
Drug: JNJ-78934804; Guselkumab · For: Colitis, Ulcerative
Sites: Scottsdale, Arizona; Sun City, Arizona; Anaheim, California · 318 sites in all
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05242484 · 577 participants · Start Sep 19, 2022 · Primary completion May 15, 2025
Drug: Guselkumab; Golimumab and 2 more · For: Colitis, Ulcerative
Sites: Arcadia, California; Coronado, California; Lancaster, California · 403 sites in all
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07577843 · 460 participants (planned) · Start May 22, 2026 · Primary completion Jun 12, 2028
Drug: JNJ-78934804; Guselkumab · For: Crohn Disease
Sites: Scottsdale, Arizona; Sun City, Arizona; Anaheim, California · 287 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Colitis, Ulcerative
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- LY4395089Phase 22 trials
Eli Lilly · Crohn Disease, Colitis, Ulcerative
- SPY001SPY001-001Phase 22 trials
Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
- SPY002SPY002-091Phase 22 trials
Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
- SPY003SPY003-207Phase 22 trials
Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.